李嘉诚还提到，自2 0 2 4年9月第一部机器到达香港后，已有5 0名患有肝癌的病人，成功接受了 治疗，他非常期待这技术发展将对新加坡和其他地区的人带来更美好的将来。据悉，李嘉诚 基金会2 0 2 4年捐赠3部用以治疗肝癌的组织碎化技术Hist o tri p s y系统予港大医学院、香港中 文大学医学院及养和医院。 来源丨南方都市报 4月3日，香港长江和记实业集团创始人李嘉诚以预录短片形式参与此次发布会，并用普通话 发表长约4分钟的致辞， 这是他近期首次公开露面。 李嘉诚以预录短片形式在发布会上露面。 李嘉诚在致辞中提到，能和淡马锡信托基金会合作，并联手送给新加坡两家医院治癌仪器， 是他的荣幸。他希望这项尖端技术能为许多与癌症战斗的病人，带来希望，减少痛楚，让患 者迅速康复，带着新的希望和活力继续生活。 在短片中，李嘉诚形容Hist o tri p s y "不可思议"，深深被其潜力震撼，并表示利用超声波来碎 化癌细胞，无创、无辐射，不用消融，确实令人惊叹。他强调，在一个极度需要医疗创新来 应对癌症的世界里，推动进步的力量，有合作精神，与慈善公益心特别重要。他认为淡马锡 信托基金会"为每一代人打造更好的未来 ...

Financial Data and Key Metrics Changes - Research and development revenue for Q4 2024 was $7.6 million, up from $5.3 million in the prior year, reflecting increased work under the BARDA PBS contract [20] - Full year 2024 R&D revenue reached $29.6 million, a 63.5% increase from $18.1 million in 2023, marking the highest revenue in the company's history [22] - Gross margin for Q4 2024 declined to 44% from 46.1% in the prior year, primarily due to a smaller percentage of direct labor on the BARDA PBS contract [21] - Full year gross margin rose to 44.9% from 43.6% in the prior year, driven by a higher reimbursement rate under the current BARDA PBS contract [22] - General and administrative expenses decreased to $4.6 million in Q4 2024 from $5.4 million in the prior year [21] Business Line Data and Key Metrics Changes - The DeepView system demonstrated exceptional performance in predicting burn healing potential, significantly outperforming clinical judgment in sensitivity, DICE score, and specificity [10][11] - The company plans to submit results to the FDA by the end of Q2 2025, seeking de novo classification in 2026 [12] Market Data and Key Metrics Changes - The response to the DeepView system in the UK and Australia has been exceptional, with strong enthusiasm from medical specialists [14] - Three DeepView systems have been successfully deployed in leading hospitals in Australia, enhancing the company's presence in the region [15] Company Strategy and Development Direction - The company is focused on advancing its DeepView technology for wound and burn assessment, with key milestones in regulatory pathways and clinical validation [8] - Plans include gathering real-world clinical feedback across multiple continents to support FDA submissions and commercialization strategies [13] - The formation of Spectral IP aims to monetize intellectual property assets within healthcare and AI sectors, with a planned spin-off into an independent publicly traded company [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's progress and the potential for growth, emphasizing a focus on finance, focus, and finish [27] - The company anticipates a revenue forecast of approximately $21.5 million for fiscal year 2025, with expectations of a step back in revenue as it prepares for FDA submission [26][45] Other Important Information - The company has received over $7 million in government funding for the development of the Snapshot M diagnostic tool, which is expected to be ready for military deployment in 2027 [16] - Total monthly operating losses were reduced from $4.6 million in the first half of 2024 to approximately $2 million in the second half [25] Q&A Session Summary Question: Plans for commercialization and staffing - The company plans to precondition the market with studies and mobilize a sales force as they anticipate FDA clearance for commercialization [31][32] Question: Revenue guidance for 2025 - The company expects a slight decrease in revenue for 2025 as it positions for FDA submission, with a ramp-up anticipated in 2026 [44][45] Question: FDA submission requirements - The submission will include a comprehensive package with multiple sections, all reviewed by BARDA before submission to the FDA [46][47] Question: DICE score significance - The DICE score is crucial for evaluating segmentation tasks and is important for FDA assessments, balancing precision and recall [51][52] Question: Future deployments in Australia and the UK - The company does not plan to expand the number of units but will focus on deeper utilization and feedback from existing sites [53][54] Question: Pediatric study timeline - Data from the pediatric study is merged with adult data, and the company feels confident in the representative sample for FDA submission [62] Question: Development milestones for Snapshot M - The company is incorporating preliminary feedback from military assessments and plans to submit further applications in 2026 [63][64] Question: Learnings from UK deployments - Positive feedback has been received from UK users, and the company anticipates sharing data at upcoming scientific meetings [67][68]

2025年1月31日， 飞利浦Philips 宣布与 心脏成像技术AI公司 Myocardial Solutions 合作，致力于推动AI赋能的心脏磁共振成像（MRI）技术的发展。 作为健康科技领域的领导者，飞利浦在 成像系统 和 AI驱动的医疗解决方案 方面拥有丰富经验。而 Myocardial Solutions 则专注于 创新的心脏MRI软件 ，能 够 评估心肌功能并检测心脏功能障碍的早期迹象。 此次合作旨在 通过整合先进的AI技术，提高心脏MRI的精准性、效率和可及性，从而更好地诊断和管理心脏疾病 （尤其是 心脏肿瘤学 ），改善癌症患者和 幸存者对心脏病的早期识别，将成像技术整合到心脏护理中来提高患者的生存率和生活质量。 飞利浦 MR 业务负责人 Ioannis Panagiotelis表示，"通过将我们创新的 BlueSeal 创新和 SmartSpeed 技术与 Myocardial Solutions 在心脏护理方面的专业知识 相结合，我们的目标是重新定义心脏护理的标准、环境责任和可及性。" # 本次合作内容 该合作伙伴关系将利用飞利浦的Fast-SENC（一种快速 MRI 采集序列）和 Myo ...